W World Corp. Stock OTC Markets

Stocks

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

13-01-02	Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer	CI
12-10-17	Pharmos Corp. Announces Management Changes	CI

13-01-02	Pharmos Corp. Designates Eric Fangmann as Acting President and Acting Chief Financial Officer	CI
12-10-17	Pharmos Corp. Announces Management Changes	CI
12-07-30	Pharmos Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	CI
12-05-17	Pharmos Corp. Announces Successfully Completion of Proof-Of-Concept Clinical Trial Using its Compound Levotofisopam to Treat Patients with Hyperuricemia and Gout	CI
12-04-16	Pharmos Corp. Announces Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2012	CI
12-04-05	Pharmos Corp. Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout	CI
12-02-17	Pharmos Corp. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011	CI

W World Corp. is a United States-based company. The Company has no operation nor generated any revenue.

Employees

Sector